Search

Displaying results 641 - 650 of 1723 in total
  1. Drug

    Clobetasol propionate

    go.drugbank.com/drugs/DB01013
    ApprovedInvestigational

    [A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]

  2. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    [L15047,L15052,L15102] Ulobetasol was granted FDA approval on 17 December 1990.[L15047]

  3. Drug

    Brivaracetam

    go.drugbank.com/drugs/DB05541
    ApprovedInvestigational

    Briviact received FDA approval on February 19, 2016 [L760].

  4. Drug

    Edetate calcium disodium anhydrous

    go.drugbank.com/drugs/DB14598
    ApprovedInvestigational

    [A204173] Edetate calcium disodium was granted FDA approval on 16 July 1953.[L12774]

  5. Drug

    Acellular nerve allograft

    go.drugbank.com/drugs/DB30293
    ApprovedInvestigational

    Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral

  6. Drug

    Vilazodone

    go.drugbank.com/drugs/DB06684
    ApprovedInvestigational

    Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].

  7. Drug

    Naltrexone

    go.drugbank.com/drugs/DB00704
    ApprovedInvestigationalVet approved

    The FDA has approved naltrexone for the treatment of alcohol dependence.

  8. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    to be approved by the FDA. … [A244815] On January 26, 2022, tebentafusp was first approved by the FDA for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.

  9. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma.

  10. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD. … [L51194,L51199] It is the first FDA-approved anti-CSF-1R antibody directed against inflammatory and fibrotic drivers in chronic graft-versus-host disease.[L51199]